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ABSTRACT 
 
The most common adverse event associated with oral anticoagulation (OAC) is bleeding in general that is seen in 5 to 48% of 
patients and gastrointestinal bleeding (GIB) in particular which occurs in 2–4% of patients. Intramural hematoma (IMH) is a 
rare variant of GIB, occurring in 1 in every 2500 patients and is treated with OACs. IMHs are rarely fatal and the current data 
suggest conservative medical therapy and clinical follow-up for management of IMHs. GIB and intestinal IMH is becoming a 
more common clinical problem because of increasing number of patients taking OACs. This report describes a 91-year-old 
woman who was presented with abdominal discomfort for 2 days. The patient had been under anticoagulant therapy with 
warfarin because of atrial fibrillation. She was found to have an inappropriately prolonged international normalized ratio level 
of 8.1. IMH was confirmed with abdominal ultrasound and computed tomography (CT) scan. The patient was treated 
conservatively with fluid resuscitation, nasogastric decompression, bowel rest and reversal of anticoagulation. Follow-up CT 
scans, approximately one month after medical treatment, demonstrated complete resolution of the IMH. Intestinal IMH 
should be considered in the differential diagnosis of acute abdomen in any anti-coagulated patient with abdominal complaints. 
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ral anticoagulant agents (OACs) with warfarin 
and direct oral anticoagulants (DOACs) 
(dabigatran, rivaroxaban, apixaban and edoxaban) 
are widely used in various clinical situations, particularly 
in cardiovascular diseases. The number of patients taking 
OACs has increased significantly in recent years, and it is 
estimated that around 2% of the population in developed 
countries are taking OACs [1-3]. Parallel to this increase, 
prevalence of complications due to the use of OACs is 
expected to increase. The most common adverse event 
associated with oral anticoagulation is bleeding in general 
that is seen in 5 to 48% of patients and gastrointestinal 
bleeding (GIB) in particular which occurs in 2–4% of 
patients [4]. Intramural hematoma (IMH) is a rare variant 
of GIB, occurring in 1 in every 2500 patients and is treated 
with OACs. GIB and intestinal IMH becoming a more 
common clinical problem because of increasing number of 
patients taking OACs; population ageing and the 
introduction of new DOACs that do not require 
monitoring. The presented case demonstrates an extensive 
warfarin-induced jejunal IMH which it is presented to raise 
awareness to this entity, and its management. 
CASE REPORT 
A 91-year-old woman with a prior history of hypertension 
and atrial fibrillation (AF) came to the hospital for nausea 
and persistent abdominal discomfort more marked in the 
epigastric region for 2 days without change in bowel habits 
or infective symptoms. The patient did not have a history 
of trauma and she had no evidence of upper or lower 
gastrointestinal bleeding. The patient had been under 
O 
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anticoagulant therapy with warfarin (Coumadin, Zentiva 
Medical) 5 mg id for 2 years because of AF. At admission, 
her hemodynamic parameters were normal and abdomen 
was distended but soft and non-tender with active bowel 
sounds. There was no evidence of peritonism. And also, 
other system examinations were unremarkable. 
Electrocardiogram revealed AF which was under rate 
control. Laboratory results showed decreased hemoglobin 
level of 10.4 g/l and inappropriately prolonged 
international normalized ratio (INR) level of 8.1. 
Abdominal ultrasound indicated proximal intestinal 
dilation and thickening involving a long segment of small 
bowel. Then, abdominal non-enhanced and enhanced 
computed tomography (CT) was performed to rule out 
acute abdominal disease. Non-enhanced CT scan showed 
homogeneous and symmetric intramural thickening with 
hyper dense material in the jejunum wall. Enhanced CT 
scan showed advanced thickening of the jejunal wall with 
free fluid collection adjacent to dilated segment of the 
jejunum (Figure 1).  
  
Figure 1: Enhanced CT demonstrated advanced 
intramural thickening of the jejunal wall with free fluid 
collection adjacent to dilated segment of the jejunum 
(narrows) 
The duodenum and the stomach were also dilated with no 
associated transition point and the distal ileum and the 
colon were decompressed. Following these morphological 
features, the patient was diagnosed as spontaneous IMH of 
the jejunum caused by over anti-coagulation. Warfarin was 
withheld and decompression was applied with a 
nasogastric catheter. Intravenous fluids were administered 
while INR was reversed with intravenous vitamin K and 
three units of fresh frozen plasma. The patient remained 
hemodynamically stable with no evidence of active 
bleeding and did not require surgical intervention or 
erythrocyte transfusion. The nasogastric catheter was 
removed three days after it was inserted and diet was 
progressed. The cardiologist consulted recommending a 
switch in anticoagulant therapy to apixaban 5 mg bid. The 
patient was discharged from the hospital on the sixth day 
with good clinical status. Follow-up CT scans 
approximately one month after medical treatment 
demonstrated complete resolution of the intramural 
hematoma (Figure 2). 
 
Figure 2: Follow-up CT scan demonstrated complete 
resolution of the intramural hematoma of the jejunum 
(narrows) 
DISCUSSION 
Intestinal IMH is a rare variant of GIB and characterized 
by separation, which of the intestinal wall layers by 
hemorrhage caused by damage in the terminal arteries in 
the submucosa [5-8]. Over 90% of cases occur secondary 
to blunt abdominal trauma [9]. The main cause of non-
traumatic ‘spontaneous’ IMH is over anticoagulation and 
has a rare occurrence i.e.  occurs in 1 in 2500 patients and 
is treated with OACs and it is seen more in men [10]. 
Clinical presentation of IMH varies depending on 
hematoma site and grade. It may range from mild non-
specific symptoms to severe obstruction and peritonitis 
[10, 11].Therefore, intestinal IMH should be considered in 
the differential diagnosis of acute abdomen in any anti-
coagulated patient with abdominal complaints [4]. 
Abdominal ultrasound is seen to be the first imaging 
evaluation but non-contrast abdominal CT is more 
valuable imaging modality that might provide more 
specific diagnostic features including circumferential 
bowel wall thickening, intramural hyper-density and 
luminal narrowing and intestinal obstruction [9]. The 
current data suggest conservative medical therapy 
including early diagnosis with appropriate fluid 
resuscitation, nasogastric decompression, bowel rest and 
reversal of anticoagulation (including anticoagulant 
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cessation, administration of intravenous vitamin K, 
prothrombin complex, fresh frozen plasma or factor 
concentrates as required) and clinical follow-up of 
obstructive symptoms for management of small-bowel 
IMH. AF has increased 12.6% over the last 20 years and is 
expected to increase further [7, 12]. Additionally, DOACs 
do not require monitoring with INR and are taken as a 
fixed dose, making them more attractive compared to 
warfarin [13]. Due to the rapid increase in DOAC 
prescription rates, the risk of GIB and intestinal IMH is 
expected to increase. 
CONCLUSION 
GIB and intestinal IMH are becoming a more common 
clinical problem. When the source of GIB associated with 
OACs is not found, intestinal IMH should be considered. 
The importance of early and accurate diagnosis is related 
to the better prognosis associated with conservative 
therapy. 
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